Akari Therapeutics Plc (AKTX)’s Financial Results Comparing With Edge Therapeutics Inc. (:)

Akari Therapeutics Plc (NASDAQ:AKTX) and Edge Therapeutics Inc. (:) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akari Therapeutics Plc 3 0.00 N/A -1.14 0.00
Edge Therapeutics Inc. N/A 0.00 N/A -1.31 0.00

In table 1 we can see Akari Therapeutics Plc and Edge Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 has Akari Therapeutics Plc and Edge Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Akari Therapeutics Plc 0.00% -367% -151.7%
Edge Therapeutics Inc. 0.00% 0% 0%

Insider & Institutional Ownership

Roughly 4.9% of Akari Therapeutics Plc shares are owned by institutional investors while 28.21% of Edge Therapeutics Inc. are owned by institutional investors. Insiders owned 57.08% of Akari Therapeutics Plc shares. On the other hand, insiders owned about 5.63% of Edge Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akari Therapeutics Plc -6.93% -11.74% -45.98% -6% -1.05% 19.75%
Edge Therapeutics Inc. 0% 0% 0% 0% 0% 0%


Akari Therapeutics Plc beats on 4 of the 6 factors Edge Therapeutics Inc.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.